Impact of Intravitreal Dexamethasone Implant (Ozurdex) on Macular Morphology and Function

Querques, Giuseppe; Lattanzio, Rosangela; Querques, Lea; Triolo, Giacinto; Cascavilla, Maria Lucia; Cavallero, Edoardo; Turco, Claudia Del; Casalino, Giuseppe; Bandello, Francesco

doi:10.1097/iae.0b013e31829f7495

Cited by 36 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This compares favourably with results from the GENEVA trial, which showed a mean reduction of 119µm at 180 days following treatment [9], as well as other studies [14,18,19]. However there was no association between change in VA and change in CRT following treatment in our study, regardless of the baseline VA. As improvement in CRT does not necessarily reflect visual improvement, we surmise that resolution of ME on OCT scanning may leave residual macular atrophy or scarring with consequently little improvement in VA.…”

Section: Anatomical Outcomessupporting

confidence: 69%

Untitled

2015

OCR

View full text Add to dashboard Cite

Section: Anatomical Outcomessupporting

confidence: 69%

Untitled

2015

OCR

View full text Add to dashboard Cite

“…Several studies reported its efficacy in decreasing CRT and improving visual function in RVO eyes [11,12,13,14,15]. However, the mechanism by which dexamethasone and other steroids reduce macular edema in RVO and the exact time course of drug action are not fully recognized yet.…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, very little data are available to date. More specifically, the earliest SD-OCT information present in the literature describes the outcomes 1 month after treatment and shows a mean reduction of CRT between 150 and 300 μm [11,12,13]. In the present study we performed a sequential series of SD-OCT evaluations at 1, 2, 3, 7, 21, 28, 60, and 90 days after treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, no conclusions can be drawn from this study on the effects of steroidal therapy on CRT sooner than 3 months after treatment initiation. Other studies investigated the efficacy of Ozurdex with a monthly OCT evaluation and showed that notable morphological improvements can be seen as soon as 1 month after treatment [11,12,13]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early Effects of Dexamethasone Implant on Macular Morphology and Visual Function in Patients with Macular Edema Secondary to Retinal Vein Occlusion

Veritti

Macor²,

Lanzetta³

2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate the early effects of the intravitreal erodible dexamethasone implant Ozurdex in patients with macular edema due to retinal vein occlusion (RVO). Methods: Eyes with macular edema due to RVO were prospectively included in the study and received a 700-μg dexamethasone implant. Best-corrected visual acuity (BCVA) measurement, complete ophthalmic evaluation and spectral-domain optical coherence tomography were performed at baseline and 1, 2, 3, 7, 14, 21, 28, 60, and 90 days after treatment. Results: Nineteen eyes of 18 patients were included in the study. Mean central retinal thickness (CRT) decreased rapidly after treatment (p < 0.0001) from 503 μm at baseline to 288 μm after 1 day and 199 μm at the end of the follow-up. BCVA gained on average +6 ETDRS letters after 1 day and +11 letters at day 90 (p = 0.0001). Conclusion: The intravitreal dexamethasone implant showed a fast effect in reducing CRT and improving BCVA in RVO patients.

show abstract

“…Further ‘real-life' studies describing series of patients treated with Ozurdex for ME due to RVO in multicentric or single-center institutional settings have found clinically meaningful benefits and no serious adverse events [10,11,12,13,14,15,16,17,18]. However, 12-month clinical data have rarely been reported in the previous literature nor has analysis on treatment-naïve eyes with recent onset disease.…”

Section: Introductionmentioning

confidence: 92%

Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors

Maggio

Polito²,

Guerriero³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate anatomical and visual outcomes following intravitreal dexamethasone implantation (Ozurdex) in eyes with visual loss due to macular edema (ME) secondary to retinal vein occlusion (RVO) and to identify predictive factors for improvement in best-corrected visual acuity (BCVA). Methods: We retrospectively analyzed medical records of 43 consecutive eyes with treatment-naïve ME secondary to recent onset RVO treated with repeated Ozurdex injections on a pro re nata basis. Results: The mean follow-up (FU) duration was 14 months (min. 12, max. 22). Both mean BCVA and central macular thickness improved significantly at the end of the FU period (p = 0.0001), and more than 30% of the eyes gained ≥3 lines within 3 months of repeated injections. Presence of foveal serous retinal detachment and macular ischemia were negatively associated with visual outcomes. Improvements were significantly associated with baseline BCVA and the integrity of the ellipsoid zone. No serious adverse events were recorded. Conclusions: In our study population, Ozurdex was a safe and effective therapeutic option for the treatment of ME associated with RVO. The results suggest that a comprehensive approach in the examination of RVO eyes may help to predict which patients are most likely to benefit from the treatment.

show abstract

Impact of Intravitreal Dexamethasone Implant (Ozurdex) on Macular Morphology and Function

Abstract: In eyes with macular edema secondary to central retinal vein occlusion, intravitreal dexamethasone provides functional benefits that correlate well with ultrastructural macular changes.

Cited by 36 publications

References 18 publications

Untitled

Untitled

Early Effects of Dexamethasone Implant on Macular Morphology and Visual Function in Patients with Macular Edema Secondary to Retinal Vein Occlusion

Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors

Contact Info

Product

Resources

About